Pfizer(US:PFE) Zhi Tong Cai Jing·2025-11-04 07:09Core Viewpoint - Pfizer (PFE.US) is set to release its Q3 earnings report on November 4, with expectations of a significant decline in both earnings per share and revenue, reflecting market concerns about the company's ability to adapt to post-pandemic demand normalization [1] Financial Performance - Expected earnings per share (EPS) for Q3 is $0.64, a year-over-year decrease of 39.6% - Projected revenue is $16.52 billion, down 6.7% year-over-year - Pfizer has exceeded EPS expectations for eight consecutive quarters, but only 63% of the time for revenue [1] Analyst Sentiment - Analysts have become increasingly cautious, with EPS expectations being downgraded 15 times and revenue expectations 10 times in the past three months - This trend indicates growing concerns regarding Pfizer's performance in the current market environment [1] Stock Performance - Year-to-date, Pfizer's stock has declined over 7%, underperforming the market, which has risen by 16% - Recent positive developments and a temporary suspension of drug import tariffs by the Trump administration may lead to a potential rebound in Pfizer's stock price [1] Strategic Initiatives - In late September, Pfizer committed to providing discounts of up to 85% on four prescription drugs through the TrumpRx pricing platform - The company also pledged to invest $70 billion in drug production and R&D in exchange for a three-year tariff exemption [1] Upcoming Developments - The upcoming earnings report is expected to shed light on Pfizer's progress in cancer treatment and the tangible impact of tariff policies on profitability - The ongoing acquisition bid for Metsera (MTSR.US) by Novo Nordisk, which raised its offer to $9 billion, will also be a focal point [2]